TP53 and prostate neoplasm: We examined 32 primary prostate tumours and three prostate tumour cell lines for mutations by PCR amplification and direct dideoxy sequencing (KLF6), and by oligonucleotide microarray (p53GeneChipTM) analysis and dideoxy sequencing (TP53).